Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics or IMUC, a biotechnology company, has presented preliminary, promising clinical data from a Phase I trial, evaluating ICT-107, the company's dendritic cell-based cancer vaccine product candidate for the treatment of glioblastoma. ICT-107 was well tolerated, and no significant adverse events were reported.
Subscribe to our email newsletter
The Phase I clinical trial of ICT-107 was conducted to evaluate the safety and tolerability of the cancer vaccine in patients with glioblastoma, the most common and malignant type of brain cancer. The trial enrolled 19 patients and was conducted at Cedars-Sinai Medical Center.
Of the 19 patients enrolled, 17 patients are still alive, with eight patients surviving at least one year after the surgery that preceded their vaccine treatment. Approximately 10 patients were evaluated for immune responses, and five of them had a significant immune response to at least one tumor-associated antigen. Patients demonstrating an immune response are exhibiting a trend toward longer overall survival, the company said.
Surasak Phuphanich, principal investigator of the trial, said: “We are encouraged by these preliminary data from ICT-107, and while we are cautious due to their preliminary nature, we are pleased that 42% of patients remain alive one year after the surgery that preceded their vaccine treatment.
“Our clinical goal with ICT-107 is to stimulate a cancer-specific immune response, so we were encouraged to see that 50% of the patients evaluated had a tumor-specific immune response.”